Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like it's out of stock on Walmart
It's been on Amazon for some time now!
Sucks!
Just got this word from ZIVO VP Tirth Patel, investors relations
Only 3 proxy items will be discussed at the meeting-Nothing else.
NO BUSINESS PRESENTATION will be made.
Tirth Patel
Vice President
T: 212-201-6614
tpatel@lhai.com
Christine Rich <crich@zivobioscience.com>
To: trprofit
Wed, Jul 27 at 11:59 AM
The shareholder meeting is being held in person only as indicated in ZIVO’s proxy statement. See link below.
https://ir.zivobioscience.com/all-sec-filings/content/0001654954-22-009260/zivo_def14a.htm
PLEASE NOTE OUR NEW ADDRESS
Christine Rich, Legal Affairs Manager
Zivo Bioscience, Inc.
21 East Long Lake Rd., Ste 100
Bloomfield Hills, MI 48304
Office (248) 452-9866, Ext 150
27 trades
613 shares traded
Would like to be part of that "conversation"
IF only, eh?
$$ITNS ITONIS https://pennystocks.today/cheap-stocks-with-potential-itonis-inc/
8000 CVS Stores???
Already sold on Amazon for years now!
In 2021 ITNS entered an agreement with CVS Pharmacy for its Test & Learn Program from which the company received two purchase orders which placed the product across 100 retail stores for a 24-week analysis phase. This was designed to provide feedback regarding the product’s success. If Emesyl meets CVS’ criteria, then an action plan will be developed by the CVS category manager to expand distribution to 8,000 stores or more. However this would likely be implemented in the “next CVS planogram cycle”.
$$ITNS ITONIS https://pennystocks.today/cheap-stocks-with-potential-itonis-inc/
8000 CVS Stores???
Already sold on Amazon for years now!
In 2021 ITNS entered an agreement with CVS Pharmacy for its Test & Learn Program from which the company received two purchase orders which placed the product across 100 retail stores for a 24-week analysis phase. This was designed to provide feedback regarding the product’s success. If Emesyl meets CVS’ criteria, then an action plan will be developed by the CVS category manager to expand distribution to 8,000 stores or more. However this would likely be implemented in the “next CVS planogram cycle”.
Came across this. News Soon???
https://pennystocks.today/cheap-stocks-with-potential-itonis-inc/
ZIVO Is ZIVO finally ready to go?
LOTS OF ACTIVITY!
ZIVO News: Securities Registration: Employee Benefit Plan (s-8) 06/22/2022 04:06:43 PM
ZIVO News: Current Report Filing (8-k) 05/20/2022 04:13:04 PM
(White Paper Submission to USDA)
ZIVO News: Zivo Bioscience (ZIVO) Receives a Buy from Maxim Group 05/20/2022 07:15:19 AM
ZIVO News: Maxim Group Thinks Zivo Bioscience’s Stock is Going to Recover 05/03/2022 02:25:12 PM
ZIVO News: Current Report Filing (8-k) 04/25/2022 04:14:31 PM
$PNDHF Pond Technologies Engages Cleantech Consultant to Accelerate Project Pipeline
June 22, 2022 News
MARKHAM, ON / ACCESSWIRE / June 22, 2022 / Pond Technologies Holdings Inc. ("Pond") (TSX.V:POND)(OTCQB:PNDHF)(FSE:4O0), an ESG company addressing global sustainability challenges of protein shortages and climate change, announces it has agreed to engage Clean Conduit, Inc., a clean technology management consulting firm. Clean Conduit, Inc. will market Pond Technologies' carbon absorbing, algae-growing technology to prospective clients.
Clean Conduit, Inc (www.cleanconduit.com) has over 15 years experience in domestic and international cleantech consulting. It offers unique, multidisciplinary services under one umbrella in the areas of professional engineering, business, and sales. Their expertise includes guiding cleantech companies through complex initiatives by articulating pathways to success and working closely with them through execution and delivery. Beyond its own extensive network, Clean Conduit, Inc. is also equipped with proven tools and techniques for market research and lead generation which will assist in building an ecosystem of entities that can support Pond Technologies' short and long- term requirements.
President & CEO at Pond, Grant Smith, said: "This engagement with Clean Conduit, largely subsidized through GreenCentre Canada, will leverage their experience, know-how, and network to provide Pond with new, meaningful introductions and client leads in industries such as alternative proteins where Pond has an amazing value proposition to offer. Given their history helping grow Canadian cleantech companies, we're confident that Clean Conduit will drive significant value for us by furthering awareness of our unique technology."
About Pond Technologies
Located in Markham, Ontario, Pond has developed a proprietary system that can profitably transform CO2 into valuable products. Its Pond Carbon business focuses on absorbing greenhouse gas emissions, transforming these into food, feed, and nutraceutical ingredients. Pond recently added a Biotech division focused on the growth of unique strains of microalgae to be used as a reproductive medium for the expression of human antibodies and proteins.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information: Grant Smith, Chief Executive Officer, at info@pondtech.com or 416-287-3835 ext. 201.
SOURCE: Pond Technologies Holdings Inc.
$PNDHF Pond Technologies Engages Cleantech Consultant to Accelerate Project Pipeline
June 22, 2022 News
MARKHAM, ON / ACCESSWIRE / June 22, 2022 / Pond Technologies Holdings Inc. ("Pond") (TSX.V:POND)(OTCQB:PNDHF)(FSE:4O0), an ESG company addressing global sustainability challenges of protein shortages and climate change, announces it has agreed to engage Clean Conduit, Inc., a clean technology management consulting firm. Clean Conduit, Inc. will market Pond Technologies' carbon absorbing, algae-growing technology to prospective clients.
Clean Conduit, Inc (www.cleanconduit.com) has over 15 years experience in domestic and international cleantech consulting. It offers unique, multidisciplinary services under one umbrella in the areas of professional engineering, business, and sales. Their expertise includes guiding cleantech companies through complex initiatives by articulating pathways to success and working closely with them through execution and delivery. Beyond its own extensive network, Clean Conduit, Inc. is also equipped with proven tools and techniques for market research and lead generation which will assist in building an ecosystem of entities that can support Pond Technologies' short and long- term requirements.
President & CEO at Pond, Grant Smith, said: "This engagement with Clean Conduit, largely subsidized through GreenCentre Canada, will leverage their experience, know-how, and network to provide Pond with new, meaningful introductions and client leads in industries such as alternative proteins where Pond has an amazing value proposition to offer. Given their history helping grow Canadian cleantech companies, we're confident that Clean Conduit will drive significant value for us by furthering awareness of our unique technology."
About Pond Technologies
Located in Markham, Ontario, Pond has developed a proprietary system that can profitably transform CO2 into valuable products. Its Pond Carbon business focuses on absorbing greenhouse gas emissions, transforming these into food, feed, and nutraceutical ingredients. Pond recently added a Biotech division focused on the growth of unique strains of microalgae to be used as a reproductive medium for the expression of human antibodies and proteins.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information: Grant Smith, Chief Executive Officer, at info@pondtech.com or 416-287-3835 ext. 201.
SOURCE: Pond Technologies Holdings Inc.
$PNDHF Pond Technologies Engages Cleantech Consultant to Accelerate Project Pipeline
June 22, 2022 News
MARKHAM, ON / ACCESSWIRE / June 22, 2022 / Pond Technologies Holdings Inc. ("Pond") (TSX.V:POND)(OTCQB:PNDHF)(FSE:4O0), an ESG company addressing global sustainability challenges of protein shortages and climate change, announces it has agreed to engage Clean Conduit, Inc., a clean technology management consulting firm. Clean Conduit, Inc. will market Pond Technologies' carbon absorbing, algae-growing technology to prospective clients.
Clean Conduit, Inc (www.cleanconduit.com) has over 15 years experience in domestic and international cleantech consulting. It offers unique, multidisciplinary services under one umbrella in the areas of professional engineering, business, and sales. Their expertise includes guiding cleantech companies through complex initiatives by articulating pathways to success and working closely with them through execution and delivery. Beyond its own extensive network, Clean Conduit, Inc. is also equipped with proven tools and techniques for market research and lead generation which will assist in building an ecosystem of entities that can support Pond Technologies' short and long- term requirements.
President & CEO at Pond, Grant Smith, said: "This engagement with Clean Conduit, largely subsidized through GreenCentre Canada, will leverage their experience, know-how, and network to provide Pond with new, meaningful introductions and client leads in industries such as alternative proteins where Pond has an amazing value proposition to offer. Given their history helping grow Canadian cleantech companies, we're confident that Clean Conduit will drive significant value for us by furthering awareness of our unique technology."
About Pond Technologies
Located in Markham, Ontario, Pond has developed a proprietary system that can profitably transform CO2 into valuable products. Its Pond Carbon business focuses on absorbing greenhouse gas emissions, transforming these into food, feed, and nutraceutical ingredients. Pond recently added a Biotech division focused on the growth of unique strains of microalgae to be used as a reproductive medium for the expression of human antibodies and proteins.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information: Grant Smith, Chief Executive Officer, at info@pondtech.com or 416-287-3835 ext. 201.
SOURCE: Pond Technologies Holdings Inc.
SEM Energy Ltd. and Pond Technologies to Initially Collaborate on Scotland Based Project with Goal to Abate 10,000 tonnes of CO2
MARKHAM, ON / ACCESSWIRE / June 16, 2022 / Pond Technologies Holdings Inc. ("Pond") (TSXV:POND)(OTCQB:PNDHF)(FSE:4O0), an ESG company addressing global sustainability challenges of protein shortages and climate change, announces it has agreed to a non-exclusive memorandum of understanding ("MOU") with technology solutions company SEM Energy Ltd. ("SEM"). Headquartered in Aberdeen, Scotland, SEM is a sustainable technology solutions company that collaborates with stakeholders across the agriculture, aquaculture, distillery and biogas markets to implement tailored end-to-end solutions for the treatment of waste products and wastewater, the recovery of nutrients, and the generation of valuable new by-products. Pond's technology will be a bolt-on solution utilized in SEM projects globally, where applicable.
https://www.accesswire.com/viewarticle.aspx?id=705311
63 followers on Stocktwits to date
OTCQB Certification - OTCQB Certification 06/13/2022
https://www.otcmarkets.com/otcapi/company/financial-report/337250/content
ZIVO Deal by the end of June? It could happen
"The Company is currently having ongoing discussions with a major animal health company to potentially license its product candidate. The Company expects a final decision on whether to move forward by the end of the second quarter of 2022."
Corporate Updates May 2022
May 20, 2022
White Paper Submission to USDA
In early May 2022, Zivo Bioscience, Inc. (the “Company”) submitted a white paper titled “A Novel Bacterially Derived Immune Modulator for Mitigation of the Effects of Coccidiosis in Poultry” to the United States Department of Agriculture (“USDA”). The white paper provides a comprehensive overview of the Company’s product candidate designed to mitigate the effects of coccidiosis in poultry, and provides descriptions of the results of the Company’s twenty completed in vivo efficacy and mechanism of action studies as well as results from numerous complementary in vitro studies. The purpose of the white paper was to detail the alignment of the Company’s lead product candidate for poultry with the USDA’s responsibility for regulating immune products intended for use in animals. The Company expects the USDA to confirm jurisdiction over the product candidate within the next eight weeks. However, the USDA may not confirm jurisdiction in this timeframe, or at all. If the USDA does not confirm regulatory authority, the Company's product candidate would likely fall under the regulatory authority of the U.S. Food and Drug Administration.
New Study in Poultry Gut Health
The Company recently began the 21st in vivo study of its novel product candidate for the treatment of coccidiosis in chickens using a third party, AH Pharma, to run the study. While the previous 20 studies validated the efficacy of the active material and helped define its mechanism of action, the present study is being performed to evaluate various potential product forms aimed at enhancing the already strong intellectual property surrounding the product, while also evaluating options for minimizing production costs to maximize profit margins.
Commercialization Strategy
The Company continues to actively pursue opportunities to license its product candidates. The Company is currently having ongoing discussions with a major animal health company to potentially license its product candidate. The Company expects a final decision on whether to move forward by the end of the second quarter of 2022.
https://www.zivobioscience.com/news-media/project-updates
ZIVO Deal by the end of June? It could happen
"The Company is currently having ongoing discussions with a major animal health company to potentially license its product candidate. The Company expects a final decision on whether to move forward by the end of the second quarter of 2022."
Corporate Updates May 2022
May 20, 2022
White Paper Submission to USDA
In early May 2022, Zivo Bioscience, Inc. (the “Company”) submitted a white paper titled “A Novel Bacterially Derived Immune Modulator for Mitigation of the Effects of Coccidiosis in Poultry” to the United States Department of Agriculture (“USDA”). The white paper provides a comprehensive overview of the Company’s product candidate designed to mitigate the effects of coccidiosis in poultry, and provides descriptions of the results of the Company’s twenty completed in vivo efficacy and mechanism of action studies as well as results from numerous complementary in vitro studies. The purpose of the white paper was to detail the alignment of the Company’s lead product candidate for poultry with the USDA’s responsibility for regulating immune products intended for use in animals. The Company expects the USDA to confirm jurisdiction over the product candidate within the next eight weeks. However, the USDA may not confirm jurisdiction in this timeframe, or at all. If the USDA does not confirm regulatory authority, the Company's product candidate would likely fall under the regulatory authority of the U.S. Food and Drug Administration.
New Study in Poultry Gut Health
The Company recently began the 21st in vivo study of its novel product candidate for the treatment of coccidiosis in chickens using a third party, AH Pharma, to run the study. While the previous 20 studies validated the efficacy of the active material and helped define its mechanism of action, the present study is being performed to evaluate various potential product forms aimed at enhancing the already strong intellectual property surrounding the product, while also evaluating options for minimizing production costs to maximize profit margins.
Commercialization Strategy
The Company continues to actively pursue opportunities to license its product candidates. The Company is currently having ongoing discussions with a major animal health company to potentially license its product candidate. The Company expects a final decision on whether to move forward by the end of the second quarter of 2022.
https://www.zivobioscience.com/news-media/project-updates
$$$ ITNS CVS CONTRACT SOON?
Info on ITNS
In 2021, the Company entered into an agreement with CVS Pharmacy to participate in their Test & Learn Program for our flagship product, Emesyl®. We initially received two purchase orders from CVS which involvedshippingEmesyl®productstotwoCVSdistributioncentersinTexas. From there, we expect the program to place Emesyl® in 100 retail stores across the country, entering into a 24-week analysis phase. We expect to gather weekly feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seems to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an action plan will be developed by the CVS category manager to expand distribution to 8000+ stores, which is typically executed in their next CVS planogram cycle. At this moment, we will see what the Test & Learn Program will tell us.
$$$ ITNS CVS CONTRACT SOON?
Info on ITNS
In 2021, the Company entered into an agreement with CVS Pharmacy to participate in their Test & Learn Program for our flagship product, Emesyl®. We initially received two purchase orders from CVS which involvedshippingEmesyl®productstotwoCVSdistributioncentersinTexas. From there, we expect the program to place Emesyl® in 100 retail stores across the country, entering into a 24-week analysis phase. We expect to gather weekly feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seems to like the uniqueness of Emesyl® with it being “Homeopathic” and the “only fast acting nasal spray” on the market. If the success criteria are met, an action plan will be developed by the CVS category manager to expand distribution to 8000+ stores, which is typically executed in their next CVS planogram cycle. At this moment, we will see what the Test & Learn Program will tell us.
Ouch!
Pond Technologies CEO Featured on BNN Bloomberg
https://finance.yahoo.com/news/pond-technologies-ceo-featured-bnn-124500001.html
Pond Announces Engagement with BioCarbN in Collaboration with Livalta/AB Agri and a Second Major Agriculture Business to Identify Methane Reducing Algae Feed Solutions in Cattle
https://finance.yahoo.com/news/pond-announces-engagement-biocarbn-collaboration-120000621.html
Pond Technologies Holdings Inc. Announces Filing of 2021 Audited Financial Statements and MD&A
https://finance.yahoo.com/news/pond-technologies-holdings-inc-announces-110000652.html
Pond Provides Update to Shareholders on AB Agri/Livalta Project Progress and Milestone Payments Received of $1.5 Million to Date
https://finance.yahoo.com/news/pond-provides-shareholders-ab-agri-120000714.html
Pond Announces Publication in Nature Scientific Reports of Successful Production of Recombinant Protein Results and Provides Update on Biotech Division
https://finance.yahoo.com/news/pond-announces-publication-nature-scientific-113000865.html
Pond Technologies Holdings Inc. Announces Filing of 2022 First Quarter Unaudited Interim Condensed Financial Statements, MD&A and Provides Business Update
https://finance.yahoo.com/news/pond-technologies-holdings-inc-announces-203000938.html
See latest AGC Tweet in Intro
Zivo Bioscience (ZIVO) Receives a Buy from Maxim Group
May 20 2022 - 07:15AM
Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Zivo Bioscience (ZIVO – Research Report) yesterday and set a price target of $9.00. The company's shares closed last Thursday at $2.85, close to its 52-week low of $2.37. According to TipRanks.com, Vendetti is a 2-star analyst with an average return of 0.6% and a 33.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, ReShape Lifesciences, and Dermata Therapeutics. Currently, the analyst consensus on Zivo Bioscience is a Moderate Buy with an average price target of $9.00. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $12.
OTC filing 12-2021 page 21,( 22 ) ground-breaking..
https://www.otcmarkets.com/otcapi/company/financial-report/314644/content
Reason for post: "projected ground-breaking date of February 2022"
This has come and gone.
In September 2020 Atlantis submitted a bid in response to a Request for Proposals and was awarded a
development project in Kenner, Louisiana (adjacent to New Orleans, Louisiana) to establish a Total Resort Destination on
Lake Pontchartrain. The projected development is a first of its kind barge based water development. Moreover, the
Louisiana Legislature enacted legislation, authorizing a long term (ninety-nine (99) year lease), which was promptly
signed by the Governor. Again COVID-19 interrupted the progress of this project, however, the Atlantis Team of Partners
is moving forward with a projected ground-breaking date of February 2022. These financial statements do not contain any
projections or adjustments that might result from the outcome of this uncertaint
Guy on stocktwits says this site is updating/has been updated
www.ask-a-pro-sports.com
Could happen again with the right news
Good to see some movement
DB last mentioned a 100 to 1 RS in his 2018 SH's letter
At .002 we'd need a 500 to 1 RS to get the pps to $1.00 (30m AS)
At .01 we'd need a 100 to 1 RS to get the pps to $1.00 (150m AS)
WAY TOO MANY SHARES!
Company has almost 15 BILLION Authorized Shares now
DB has wanted to uplist for a long time, and in order to do so he has to get the number of AS under control and get the pps up in value.
Example: with a 500 to 1 RS, One million shares would be reduced to 2000 shares.
The current 15b AS would be reduced to 30m shares.
The current pps of .002 would be increased to $1.00 pps.
Gotta remember that Reverse Splits can be really ugly.
Ticker remains the same.
Now we wait for the RS to get the resulting PPS to $1.00 (or so)
DB has wanted to be able to uplist for a LONG time
Current pps is at .0020 (or so)
PPS would be $1.00 (or so) after a 500 to 1 RS.
Post on Stocktwits (from DB?) about SH letter coming this month (Feb)
Remember this from 2018 SH's letter?
100 to 1 pps mentioned below
Note At todays price of $.002 pps it would take a 500 to 1 RS to get to $1.00 pps.
ATLANTIS INTERNET GROUP CONVERSION TO ATLANTIS GAMING STOCK PLAN
As a result of our accomplishments over the last two years, the development of AGC’s Daily Fantasy Sports software, and the formation of the new partnerships with Bet Construct, Casino Technology, and other vendors, AGC is offering a buyback of ATIG stock in the form of a stock swap for AGC stock. Based on discussions with our accountants, financial advisors, lawyers and consultants, we have projected a buyback clause using a market price of One Dollar ($1.00) per share after a 100 to 1 reverse split on ATIG shares. DraftKings and Fanduel enjoy attractive valuations, up to a billion dollarsdollars per company, and we believe our fantasy sports product rivals the market leaders. Therefore, AGC offers all ATIG stockholders the opportunity to swap current ATIG stock for AGC stock. The AGC stock will be unrestricted and the ATIG stock, once converted, will become free trading. To preserve AGC’s stock price, our advisors recommend we remain a privately organized entity until the appropriate time (based on market conditions) to launch AGC publicly is appropriately identified. Our financial advisors have completed ninety-five percent (95%) of the transactional documentation to file the requisite “S1” documentation. Strategically, we continue to monitor the markets relative to a potential Initial Public Offering (“IPO”), wherein ATIG stockholders would be authorized to sell ten percent (10%) of all free trading shares, with the ability to sell all remaining shares after a six (6) months waiting period.